Get the Stockscreener App
2.79
0.36%
+0.02
OncoCyte Corporation stock is currently priced at $2.79, with a 24-hour trading volume of 7,036.
It has seen a +0.36% increased in the last 24 hours and a -4.14% declined in the past month.
The chart indicates a potential bullish trend, as the stock is above the $2.73 pivot point. If it approaches the $2.88 resistance level, significant changes may occur.
Previous Close:
$2.77
Open:
$2.83
24h Volume:
7,036
Market Cap:
$36.95M
Revenue:
$1.46M
Net Income/Loss:
$-56.77M
P/E Ratio:
-0.2717
EPS:
-10.27
Net Cash Flow:
$-29.23M
1W Performance:
+11.65%
1M Performance:
-4.14%
6M Performance:
+19.31%
1Y Performance:
+964.32%
1D Range:
$2.7156
$2.83
52W Range:
$0.19
$4.64
OncoCyte Corporation Stock (OCX) Company Profile
Name
OncoCyte Corporation
Sector
Industry
Phone
510-775-0515
Address
1010 Atlantic Avenue, Suite 102, Alameda, CA
OncoCyte Corporation Stock (OCX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| May-24-22 | Downgrade | Stephens | Overweight → Equal-Weight |
| Mar-14-22 | Downgrade | KeyBanc Capital Markets | Overweight → Sector Weight |
| Jan-07-22 | Initiated | Stephens | Overweight |
| Jan-06-22 | Resumed | Piper Sandler | Overweight |
| Mar-17-21 | Resumed | Needham | Buy |
| Jan-07-21 | Upgrade | The Benchmark Company | Speculative Buy → Buy |
| Dec-16-20 | Upgrade | Piper Sandler | Neutral → Overweight |
| Nov-30-20 | Initiated | BTIG Research | Buy |
| Nov-10-20 | Initiated | KeyBanc Capital Markets | Overweight |
| Jul-30-20 | Reiterated | The Benchmark Company | Speculative Buy |
| Jul-01-20 | Downgrade | Piper Sandler | Overweight → Neutral |
| Jun-30-20 | Downgrade | Chardan Capital Markets | Buy → Neutral |
| Jun-02-20 | Initiated | Needham | Buy |
| Feb-13-19 | Initiated | Piper Jaffray | Overweight |
| Jan-29-19 | Upgrade | Janney | Neutral → Buy |
| Dec-19-18 | Resumed | Lake Street | Buy |
View All
OncoCyte Corporation Stock (OCX) Latest News
Why Ultragenyx Pharmaceutical Shares Are Trading Lower By Around 9%? Here Are Other Stocks Moving In Monday's Mid-Day Session
Benzinga
Why Medical Properties Trust Shares Are Trading Higher By Around 13%; Here Are 20 Stocks Moving Premarket
Benzinga
Top 3 Health Care Stocks That May Collapse In Q2
Benzinga
Oncocyte Reports Full Year 2023 Financial Results
GlobeNewswire Inc.
Why NextPlat Shares Are Trading Higher By Around 30%; Here Are 20 Stocks Moving Premarket
Benzinga
Oncocyte Corporation Announces $15.8 Million Private Placement of Securities Priced At-The-Market Under Nasdaq Rules
GlobeNewswire Inc.
OncoCyte Corporation Stock (OCX) Financials Data
OncoCyte Corporation (OCX) Revenue 2024
OCX reported a revenue (TTM) of $1.46 million for the quarter ending September 30, 2023, a +216.48% rise year-over-year.
OncoCyte Corporation (OCX) Net Income 2024
OCX net income (TTM) was -$56.77 million for the quarter ending September 30, 2023, a +11.04% increase year-over-year.
OncoCyte Corporation (OCX) Cash Flow 2024
OCX recorded a free cash flow (TTM) of -$29.23 million for the quarter ending September 30, 2023, a +37.71% increase year-over-year.
OncoCyte Corporation (OCX) Earnings per Share 2024
OCX earnings per share (TTM) was -$9.46 for the quarter ending September 30, 2023, a +27.79% growth year-over-year.
About OncoCyte Corporation
OncoCyte Corporation focuses on the development and commercialization of novel and non-invasive blood and urine (liquid biopsy) diagnostic tests for the early detection of cancer. The company is developing diagnostic tests using genetic and protein markers expressed in various types of cancer. It develops diagnostic tests based on liquid biopsies using blood or urine samples for detecting lung, bladder, and breast cancer. The company was founded in 2009 and is based in Alameda, California. OncoCyte Corporation is a subsidiary of BioTime, Inc.
0.58%
1.56%
Cap:
|
Volume (24h):